Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous tumor infiltrating lymphocytes C-TIL052A
- Development stage
- Phase 1
- Lead developer
- AbelZeta, Inc.
- Modality
- Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous tumor infiltrating lymphocytes C-TIL052A is a cell therapy product consisting of T cells (tumor-infiltrating lymphocytes, or TILs) that are isolated from a patient's own resected tumor tissue and expanded ex vivo. These T cells are then infused back into the patient to target and kill cancer cells. The therapy leverages the natural ability of TILs to recognize and attack tumor-specific antigens, aiming to enhance anti-tumor immune responses. It is being developed primarily for advanced cervical cancer and other solid tumors[1][3][4][5][6]. The product has been evaluated in early-phase clinical trials for safety and anti-tumor activity.
- Other names
- autologous tumor infiltrating lymphocytes C-TIL052A
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)
Beyond the preview
Go deeper on autologous tumor infiltrating lymphocytes C-TIL052A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous tumor infiltrating lymphocytes C-TIL052A.